Back to results
US 2022/0178911 A1Published application
Synthetic Lethality Screening Platform for Cells Undergoing ALT
AssigneeThe Regents of the University of California
InventorsDirk Friedrich Hockemeyer, Timothy K. Turkalo
Life of this patent
Estimating the term…
Abstract
An in vitro culture system of human embryonic stem (hES) derived cells is used as a synthetic lethality screening platform for cells undergoing alternative lengthening of telomeres (ALT).
Claims15
An in vitro culture of human embryonic stem derived cells immortalized through the alternative lengthening of telomeres (ALT) pathway, wherein the cells comprise:
- (a) a genetic disruption of TERT locus that is:
- (i) a heterozygous genetic disruption of the TERT locus;
- or
- (ii) a homozygous genetic disruption of the TERT locus and a heterologous TERT allele operable as a conditional allele;
- (b) a genetic disruption of the CDKN2A locus;
- and
- (c) a genetic disruption of the ATRX locus,
- wherein the culture is configured and operative as a synthetic lethality screening platform to identify gene products or drugs that interfere with ALT or recombination.
5 more elements
Dependencies are inferred from the claim text.